{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:02:03Z","timestamp":1774627323121,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"DOI":"10.1186\/s12896-026-01113-5","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:05:45Z","timestamp":1771859145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metformin potentiates DSF\/Cu-loaded pluronic nanoparticles to improve therapeutic efficacy in triple-negative breast cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Mehdi","family":"Pourbakhsh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abolfazl","family":"Doustmihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoud","family":"Jabraili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marziyeh","family":"Fathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rana","family":"Jahanban Esfahlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"1","key":"1113_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/2211738507666190122111224","volume":"7","author":"FA Fisusi","year":"2019","unstructured":"Fisusi FA, Akala EO. Drug combinations in breast cancer therapy. Pharm Nanatechnol. 2019;7(1):3\u201323.","journal-title":"Pharm Nanatechnol"},{"issue":"1","key":"1113_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12943-023-01805-y","volume":"22","author":"F Ye","year":"2023","unstructured":"Ye F, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22(1):105.","journal-title":"Mol Cancer"},{"issue":"9","key":"1113_CR3","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.3390\/ijms20092272","volume":"20","author":"B Medeiros","year":"2019","unstructured":"Medeiros B, Allan AL. Molecular mechanisms of breast cancer metastasis to the lung: clinical and experimental perspectives. Int J Mol Sci. 2019;20(9):2272.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1113_CR4","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini G, et al. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Reviews Clin Oncol. 2016;13(11):674\u201390.","journal-title":"Nat Reviews Clin Oncol"},{"issue":"4","key":"1113_CR5","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.bbrc.2017.03.164","volume":"486","author":"Y-J Kim","year":"2017","unstructured":"Kim Y-J, et al. Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells. Biochem Biophys Res Commun. 2017;486(4):1069\u201376.","journal-title":"Biochem Biophys Res Commun"},{"key":"1113_CR6","doi-asserted-by":"publisher","first-page":"118543","DOI":"10.1016\/j.biopha.2025.118543","volume":"191","author":"V Ghassemifar","year":"2025","unstructured":"Ghassemifar V, et al. Harnessing nanotechnology to modulate hypoxic tumor microenvironments: enhanced strategies for oncological innovations. Biomed Pharmacother. 2025;191:118543.","journal-title":"Biomed Pharmacother"},{"key":"1113_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jconrel.2023.09.029","volume":"363","author":"A Doustmihan","year":"2023","unstructured":"Doustmihan A, et al. Molecular targets, therapeutic agents and multitasking nanoparticles to deal with cancer stem cells: A narrative review. J Controlled Release. 2023;363:57\u201383.","journal-title":"J Controlled Release"},{"issue":"7","key":"1113_CR8","first-page":"965","volume":"11","author":"S-Y Park","year":"2019","unstructured":"Park S-Y, Choi J-H, Nam J-S. Targeting Cancer Stem Cells triple-negative Breast Cancer Cancers. 2019;11(7):965.","journal-title":"Targeting Cancer Stem Cells triple-negative Breast Cancer Cancers"},{"key":"1113_CR9","doi-asserted-by":"crossref","unstructured":"Mirahmad Mazloomi HH, Esfahlan RJ. SpheroidSync as edge cutting transfer strategy for uniform and robust MCF7 spheroids in 3D culture. Scientific Reports. 2025.","DOI":"10.1038\/s41598-025-25202-1"},{"key":"1113_CR10","doi-asserted-by":"crossref","unstructured":"Mazloomi M, et al. Advanced drug delivery platforms target cancer stem cells. Asian J Pharm Sci. 2025;101036.","DOI":"10.1016\/j.ajps.2025.101036"},{"key":"1113_CR11","doi-asserted-by":"publisher","first-page":"101626","DOI":"10.1016\/j.mtbio.2025.101626","volume":"31","author":"S Karimi","year":"2025","unstructured":"Karimi S, et al. For and against tumor microenvironment: Nanoparticle-based strategies for active cancer therapy. Mater Today Bio. 2025;31:101626.","journal-title":"Mater Today Bio"},{"issue":"1","key":"1113_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13058-016-0712-6","volume":"18","author":"M Peiris-Pag\u00e8s","year":"2016","unstructured":"Peiris-Pag\u00e8s M, et al. Cancer stem cell metabolism. Breast Cancer Res. 2016;18(1):55.","journal-title":"Breast Cancer Res"},{"issue":"19","key":"1113_CR13","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1001\/jama.2019.3805","volume":"321","author":"J Flory","year":"2019","unstructured":"Flory J, Lipska K. Metformin in 2019. JAMA. 2019;321(19):1926\u20137.","journal-title":"JAMA"},{"issue":"7","key":"1113_CR14","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1007\/s10238-023-01051-y","volume":"23","author":"H Zhu","year":"2023","unstructured":"Zhu H, et al. Molecular mechanisms of action of metformin: latest advances and therapeutic implications. Clin Experimental Med. 2023;23(7):2941\u201351.","journal-title":"Clin Experimental Med"},{"issue":"2","key":"1113_CR15","doi-asserted-by":"publisher","first-page":"998","DOI":"10.3390\/curroncol31020075","volume":"31","author":"L Szablewski","year":"2024","unstructured":"Szablewski L. Insulin resistance: the increased risk of cancers. Curr Oncol. 2024;31(2):998\u20131027.","journal-title":"Curr Oncol"},{"issue":"2","key":"1113_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10911-019-09429-z","volume":"24","author":"J Faria","year":"2019","unstructured":"Faria J, et al. Metformin and breast cancer: molecular targets. J Mammary Gland Biol Neoplasia. 2019;24(2):111\u201323.","journal-title":"J Mammary Gland Biol Neoplasia"},{"issue":"13","key":"1113_CR17","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.4161\/cc.8.13.8814","volume":"8","author":"B Liu","year":"2009","unstructured":"Liu B, et al. Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle. 2009;8(13):2031\u201340.","journal-title":"Cell Cycle"},{"issue":"1","key":"1113_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/celldisc.2017.10","volume":"3","author":"P Shi","year":"2017","unstructured":"Shi P, et al. Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discovery. 2017;3(1):1\u201313.","journal-title":"Cell Discovery"},{"issue":"2","key":"1113_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.4161\/cc.11.2.18813","volume":"11","author":"X-S Deng","year":"2012","unstructured":"Deng X-S, et al. Metformin targets Stat3 to inhibit cell growth and induce apoptosis in triple-negative breast cancers. Cell Cycle. 2012;11(2):367\u201376.","journal-title":"Cell Cycle"},{"key":"1113_CR20","doi-asserted-by":"crossref","unstructured":"Wahdan-Alaswad RS, Thor AD. Metformin activity against breast cancer: mechanistic differences by molecular subtype and metabolic conditions, in Metformin. 2020. IntechOpen.","DOI":"10.5772\/intechopen.91183"},{"issue":"1","key":"1113_CR21","first-page":"129","volume":"4","author":"R Wahdan-Alaswad","year":"2018","unstructured":"Wahdan-Alaswad R, et al. Metformin targets glucose metabolism in triple negative breast cancer. J Oncol Translational Res. 2018;4(1):129.","journal-title":"J Oncol Translational Res"},{"issue":"6","key":"1113_CR22","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1007\/s12672-014-0188-8","volume":"5","author":"RS Wahdan-Alaswad","year":"2014","unstructured":"Wahdan-Alaswad RS, et al. Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b. Horm Cancer. 2014;5(6):374\u201389.","journal-title":"Horm Cancer"},{"issue":"3","key":"1113_CR23","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/antibiotics12030524","volume":"12","author":"J Lanz","year":"2023","unstructured":"Lanz J, et al. Disulfiram: mechanisms, applications, and challenges. Antibiotics. 2023;12(3):524.","journal-title":"Antibiotics"},{"issue":"30","key":"1113_CR24","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.2174\/1381612825666190816233755","volume":"25","author":"Q Yang","year":"2019","unstructured":"Yang Q, et al. An updated review of disulfiram: molecular targets and strategies for cancer treatment. Curr Pharm Design. 2019;25(30):3248\u201356.","journal-title":"Curr Pharm Design"},{"issue":"2","key":"1113_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s00280-020-04216-8","volume":"87","author":"C Lu","year":"2021","unstructured":"Lu C, et al. Disulfiram: a novel repurposed drug for cancer therapy. Cancer Chemother Pharmacol. 2021;87(2):159\u201372.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"12","key":"1113_CR26","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1097\/CM9.0000000000002909","volume":"137","author":"M Zeng","year":"2024","unstructured":"Zeng M, et al. Disulfiram: a novel repurposed drug for cancer therapy. Chin Med J. 2024;137(12):1389\u201398.","journal-title":"Chin Med J"},{"issue":"6","key":"1113_CR27","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.drudis.2020.04.003","volume":"25","author":"H Li","year":"2020","unstructured":"Li H, et al. The combination of Disulfiram and copper for cancer treatment. Drug Discovery Today. 2020;25(6):1099\u2013108.","journal-title":"Drug Discovery Today"},{"issue":"1","key":"1113_CR28","doi-asserted-by":"publisher","first-page":"101727","DOI":"10.1016\/j.mtbio.2025.101727","volume":"32","author":"M Pourbakhsh","year":"2025","unstructured":"Pourbakhsh M, et al. Poloxamer-based drug delivery systems: frontiers for treatment of solid tumors. Mater Today Bio. 2025;32(1):101727.","journal-title":"Mater Today Bio"},{"issue":"1","key":"1113_CR29","doi-asserted-by":"publisher","first-page":"112526","DOI":"10.1016\/j.ejmech.2020.112526","volume":"206","author":"I Jarak","year":"2020","unstructured":"Jarak I, et al. Pluronic-based nanovehicles: recent advances in anticancer therapeutic applications. Eur J Med Chem. 2020;206(1):112526.","journal-title":"Eur J Med Chem"},{"issue":"2","key":"1113_CR30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jconrel.2008.04.013","volume":"130","author":"EV Batrakova","year":"2008","unstructured":"Batrakova EV, Kabanov AV. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Controlled Release. 2008;130(2):98\u2013106.","journal-title":"J Controlled Release"},{"key":"1113_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-025-03206-1","author":"A Doustmihan","year":"2025","unstructured":"Doustmihan A, Jaymand M, Fathi M, Jahanban Esfahlan R., Engineered pluronic nanomicelles containing ATRA and sodium butyrate for selective TNBC differentiation therapy. Med Oncol. 2025. https:\/\/doi.org\/10.1007\/s12032-025-03206-1.","journal-title":"Med Oncol"},{"issue":"1","key":"1113_CR32","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11033-025-10241-8","volume":"52","author":"M Fakeri","year":"2025","unstructured":"Fakeri M, et al. Targeted apoptosis in breast cancer cells via niosome-mediated delivery of cyclophosphamide and sodium oxamate. Mol Biol Rep. 2025;52(1):139.","journal-title":"Mol Biol Rep"},{"issue":"2","key":"1113_CR33","first-page":"390","volume":"15","author":"S Alimohammadvand","year":"2025","unstructured":"Alimohammadvand S, et al. Tumor microenvironment responsive TPZ-Loaded Core-Shell polymeric nanoparticles for selective cancer bioreductive therapy. Adv Pharm Bull. 2025;15(2):390\u2013405.","journal-title":"Adv Pharm Bull"},{"key":"1113_CR34","doi-asserted-by":"publisher","DOI":"10.34172\/apb.2024.054","author":"MAA-A Mohammad Shahpouri","year":"2024","unstructured":"Mohammad Shahpouri MAA-A, Mahmudi H, Ghiasvand S, Dadashi H, Salemi A, Alimohammadvand S, Roshangar L, Barzegari A. Mehdi Jaymand, Rana Jahanban-Esfahlan, Dual-stage acting dendrimeric nanoparticle for deepened chemotherapeutic drug delivery to tumor cells. Adv Pharm Bull. 2024. https:\/\/doi.org\/10.34172\/apb.2024.054.","journal-title":"Adv Pharm Bull"},{"key":"1113_CR35","doi-asserted-by":"publisher","first-page":"132940","DOI":"10.1016\/j.ijbiomac.2024.132940","volume":"272","author":"H Mahmudi","year":"2024","unstructured":"Mahmudi H, et al. Self-activating chitosan-based nanoparticles for sphingosin-1 phosphate modulator delivery and selective tumor therapy. Int J Biol Macromol. 2024;272:132940.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"1113_CR36","doi-asserted-by":"publisher","first-page":"29308","DOI":"10.1038\/s41598-025-14704-7","volume":"15","author":"M Kaveh Zenjanab","year":"2025","unstructured":"Kaveh Zenjanab M, et al. Dual-loaded niosome-dendrimer nanoplatform enhances Tirapazamine delivery to hypoxic breast cancer cells. Sci Rep. 2025;15(1):29308.","journal-title":"Sci Rep"},{"issue":"1","key":"1113_CR37","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s11033-025-10835-2","volume":"52","author":"MH Hooshiar","year":"2025","unstructured":"Hooshiar MH, et al. Curcumin and Silibinin loaded pegylated nanoniosome for cancer therapy: bioinformatics and in vitro study. Mol Biol Rep. 2025;52(1):737.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"1113_CR38","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1186\/s12935-025-03977-7","volume":"25","author":"A Salemi","year":"2025","unstructured":"Salemi A, et al. Niosome-loaded Silibinin and methotrexate for synergistic breast cancer combination chemotherapy: in Silico and in vitro study. Cancer Cell Int. 2025;25(1):336.","journal-title":"Cancer Cell Int"},{"issue":"7","key":"1113_CR39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s12032-025-02796-0","volume":"42","author":"Z Hashemi","year":"2025","unstructured":"Hashemi Z, et al. Hyaluronic acid-modified theranostic niosomes for targeted Fingolimod delivery and Inhibition of triple-negative breast cancer metastasis. Med Oncol. 2025;42(7):256.","journal-title":"Med Oncol"},{"key":"1113_CR40","doi-asserted-by":"crossref","unstructured":"Dadashi H, et al. Chitosan nanoparticles loaded with metformin and digoxin synergistically inhibit MCF-7 breast cancer cells through suppression of NOTCH-1 and HIF-1\u03b1 gene expression. Int J Biol Macromol. 2024;138418.","DOI":"10.1016\/j.ijbiomac.2024.138418"},{"issue":"1","key":"1113_CR41","doi-asserted-by":"publisher","first-page":"41237","DOI":"10.1038\/s41598-025-25202-1","volume":"15","author":"M Mazloomi","year":"2025","unstructured":"Mazloomi M, Hamishehkar H, Jahanban R, Esfahlan. SpheroidSync as edge cutting transfer strategy for uniform and robust MCF7 spheroids in 3D culture. Sci Rep. 2025;15(1):41237.","journal-title":"Sci Rep"},{"issue":"6","key":"1113_CR42","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.21873\/anticanres.13410","volume":"39","author":"T Hero","year":"2019","unstructured":"Hero T, et al. The Triple-negative breast cancer cell line MDA-MB 231 is specifically inhibited by the ionophore salinomycin. Anticancer Res. 2019;39(6):2821\u20137.","journal-title":"Anticancer Res"},{"issue":"5","key":"1113_CR43","doi-asserted-by":"publisher","first-page":"R59","DOI":"10.1186\/bcr1610","volume":"8","author":"C Sheridan","year":"2006","unstructured":"Sheridan C, et al. CD44+\/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8(5):R59.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"1113_CR44","doi-asserted-by":"publisher","first-page":"18181","DOI":"10.1038\/s41598-024-65508-0","volume":"14","author":"AN Hakeem","year":"2024","unstructured":"Hakeem AN, et al. Piperine enhances doxorubicin sensitivity in triple-negative breast cancer by targeting the PI3K\/Akt\/mTOR pathway and cancer stem cells. Sci Rep. 2024;14(1):18181.","journal-title":"Sci Rep"},{"issue":"7","key":"1113_CR45","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/pharmaceutics15071796","volume":"15","author":"O Obidiro","year":"2023","unstructured":"Obidiro O, Battogtokh G, Akala EO. Triple negative breast cancer treatment options and limitations: future outlook. Pharmaceutics. 2023;15(7):1796.","journal-title":"Pharmaceutics"},{"issue":"1","key":"1113_CR46","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","volume":"9","author":"Y Xia","year":"2024","unstructured":"Xia Y, et al. Drug repurposing for cancer therapy. Signal Transduct Target Therapy. 2024;9(1):92.","journal-title":"Signal Transduct Target Therapy"},{"issue":"1","key":"1113_CR47","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discovery. 2019;18(1):41\u201358.","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"1113_CR48","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/ph17030396","volume":"17","author":"KA Corleto","year":"2024","unstructured":"Corleto KA, Strandmo JL, Giles ED. Metformin and breast cancer: current findings and future perspectives from preclinical and clinical studies. Pharmaceuticals. 2024;17(3):396.","journal-title":"Pharmaceuticals"},{"issue":"1","key":"1113_CR49","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.biochi.2025.03.002","volume":"233","author":"RS Pal","year":"2025","unstructured":"Pal RS, et al. Metformin\u2019s anticancer odyssey: revealing multifaceted mechanisms across diverse neoplastic terrains-a critical review. Biochimie. 2025;233(1):109\u201321.","journal-title":"Biochimie"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12896-026-01113-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-026-01113-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-026-01113-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T15:02:50Z","timestamp":1774623770000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12896-026-01113-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1113"],"URL":"https:\/\/doi.org\/10.1186\/s12896-026-01113-5","relation":{},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"35"}}